The Significance of the Crosstalk Between Ubiquitination or Deubiquitination and NcRNAs in Non-small Cell Lung Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Feb 2

PMID 36727069

Authors

Yiyang Sun

Ping He

Li Li

Xue Ding

Affiliations

Soon will be listed here.

Abstract

Lung cancer (LC) remains the leading cause of cancer-related deaths worldwide, with extremely high morbidity and mortality rates. Non-small cell lung cancer (NSCLC) is the most critical type of LC. It seriously threatens the life and health of patients because of its early metastasis, late clinical symptoms, limited early screening methods, and poor treatment outcomes. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), participate in cell proliferation, metastasis, and chemoresistance. Several previous studies have proven that ncRNAs are vital regulators of tumorigenesis. Ubiquitination plays the most crucial role in protein post-translational modification (PTM). Deubiquitination and ubiquitination form a homeostasis. In summary, ubiquitination and deubiquitination play essential roles in mediating the degradation or overexpression of a range of crucial proteins in various cancers. A growing number of researchers have found that interactions between ncRNAs and ubiquitination (or deubiquitination) play a crucial role in NSCLC. This review presents several typical examples of the important effects of ncRNAs and ubiquitination (or deubiquitination) in NSCLC, aiming to provide more creative ideas for exploring the diagnosis and treatment of NSCLC.

Citing Articles

Regulation and Therapeutic Application of Long non-Coding RNA in Tumor Angiogenesis.

Zhang S, Xia Y, Chen W, Dong H, Cui B, Liu C Technol Cancer Res Treat. 2024; 23:15330338241273239.

PMID: 39110070 PMC: 11307360. DOI: 10.1177/15330338241273239.

Hsa_circ_0096157 silencing suppresses autophagy and reduces cisplatin resistance in non-small cell lung cancer by weakening the Nrf2/ARE signaling pathway.

Lu H, Kong J, Cai S, Huang H, Luo J, Liu L Mol Biol Rep. 2024; 51(1):703.

PMID: 38822881 DOI: 10.1007/s11033-024-09552-z.

mA modification of lncRNA PHKA1-AS1 enhances Actinin Alpha 4 stability and promotes non-small cell lung cancer metastasis.

Guo Q, Zhang G, Zhou W, Lu Y, Chen X, Deng Z MedComm (2020). 2024; 5(6):e547.

PMID: 38764726 PMC: 11099756. DOI: 10.1002/mco2.547.

Crosstalk between ubiquitin ligases and ncRNAs drives cardiovascular disease progression.

You J, Wen Z, Tian J, Lv X, Li R, Li S Front Immunol. 2024; 15:1335519.

PMID: 38515760 PMC: 10954775. DOI: 10.3389/fimmu.2024.1335519.

Non-coding RNAs in lung cancer: molecular mechanisms and clinical applications.

Liu Y, Ding W, Wang J, Ao X, Xue J Front Oncol. 2023; 13:1256537.

PMID: 37746261 PMC: 10514911. DOI: 10.3389/fonc.2023.1256537.

References

Li W, Huang K, Wen F, Cui G, Guo H, He Z . Intermittent hypoxia-induced downregulation of microRNA-320b promotes lung cancer tumorigenesis by increasing CDT1 via USP37. Mol Ther Nucleic Acids. 2021; 24:528-541. PMC: 8056179. DOI: 10.1016/j.omtn.2020.12.023. View

Wu X, Ye W, Gong Y . The Role of RNA Methyltransferase in Normal and Malignant Hematopoiesis. Front Oncol. 2022; 12:873903. PMC: 9095908. DOI: 10.3389/fonc.2022.873903. View

Sato H, Shien K, Tomida S, Okayasu K, Suzawa K, Hashida S . Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features. Sci Rep. 2017; 7:40847. PMC: 5233972. DOI: 10.1038/srep40847. View

Zhu X, Kudo M, Huang X, Sui H, Tian H, Croce C . Frontiers of MicroRNA Signature in Non-small Cell Lung Cancer. Front Cell Dev Biol. 2021; 9:643942. PMC: 8058364. DOI: 10.3389/fcell.2021.643942. View

Luo Y, Li J, Yu P, Sun J, Hu Y, Meng X . Targeting lncRNAs in programmed cell death as a therapeutic strategy for non-small cell lung cancer. Cell Death Discov. 2022; 8(1):159. PMC: 8980082. DOI: 10.1038/s41420-022-00982-x. View

Li L, Guo G, Zhang H, Zhou B, Bai L, Chen H . Association between H19 SNP rs217727 and lung cancer risk in a Chinese population: a case control study. BMC Med Genet. 2018; 19(1):136. PMC: 6090654. DOI: 10.1186/s12881-018-0573-1. View

Tong G, Tong W, He R, Cui Z, Li S, Zhou B . MALAT1 Polymorphisms and Lung Cancer Susceptibility in a Chinese Northeast Han Population. Int J Med Sci. 2022; 19(8):1300-1306. PMC: 9346381. DOI: 10.7150/ijms.73026. View

Yu X, Fu X, Zhang X, Bai C, Wang Y . Circ_0001658 regulates gefitinib resistance of non-small cell lung cancer through miR-409-3p/TWIST1 axis. Anticancer Drugs. 2021; 33(2):158-166. DOI: 10.1097/CAD.0000000000001257. View

Li Y, Dong R, Lu M, Cheng C, Feng Z, Zhao R . Let-7b-3p inhibits tumor growth and metastasis by targeting the BRF2-mediated MAPK/ERK pathway in human lung adenocarcinoma. Transl Lung Cancer Res. 2021; 10(4):1841-1856. PMC: 8107730. DOI: 10.21037/tlcr-21-299. View

10.

Huang Y, Xia L, Tan X, Zhang J, Zeng W, Tan B . Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis. Cell Mol Biol Lett. 2022; 27(1):43. PMC: 9164758. DOI: 10.1186/s11658-022-00343-7. View

11.

Wei H, Li L, Zhang H, Xu F, Chen L, Che G . Circ-FOXM1 knockdown suppresses non-small cell lung cancer development by regulating the miR-149-5p/ATG5 axis. Cell Cycle. 2021; 20(2):166-178. PMC: 7889128. DOI: 10.1080/15384101.2020.1867780. View

12.

Zhang P, Li L, Wang B, Ran X, Yang S, Luo Y . miR-489-3p promotes malignant progression of non-small cell lung cancer through the inactivation of Wnt/β-catenin signaling pathway via regulating USP48. Respir Res. 2022; 23(1):93. PMC: 9006470. DOI: 10.1186/s12931-022-01988-w. View

13.

Spolverini A, Fuchs G, Bublik D, Oren M . let-7b and let-7c microRNAs promote histone H2B ubiquitylation and inhibit cell migration by targeting multiple components of the H2B deubiquitylation machinery. Oncogene. 2017; 36(42):5819-5828. PMC: 5600258. DOI: 10.1038/onc.2017.187. View

14.

Mi J, Zou Y, Lin X, Lu J, Liu X, Zhao H . Dysregulation of the miR-194-CUL4B negative feedback loop drives tumorigenesis in non-small-cell lung carcinoma. Mol Oncol. 2017; 11(3):305-319. PMC: 5527444. DOI: 10.1002/1878-0261.12038. View

15.

Cole A, Clifton-Bligh R, Marsh D . Histone H2B monoubiquitination: roles to play in human malignancy. Endocr Relat Cancer. 2014; 22(1):T19-33. DOI: 10.1530/ERC-14-0185. View

16.

Cheng Q, Zhang S, Zhong B, Chen Z, Peng F . Asiatic acid re-sensitizes multidrug-resistant A549/DDP cells to cisplatin by down regulating long non-coding RNA metastasis associated lung adenocarcinoma transcript 1/β-catenin signaling. Bioengineered. 2022; 13(5):12972-12984. PMC: 9275950. DOI: 10.1080/21655979.2022.2079302. View

17.

Qu J, Lin Z . Autophagy Regulation by Crosstalk between miRNAs and Ubiquitination System. Int J Mol Sci. 2021; 22(21). PMC: 8585084. DOI: 10.3390/ijms222111912. View

18.

Huang X, Chen J, Cao W, Yang L, Chen Q, He J . The many substrates and functions of NEDD4-1. Cell Death Dis. 2019; 10(12):904. PMC: 6885513. DOI: 10.1038/s41419-019-2142-8. View

19.

Lou M, Gao Z, Zhu T, Mao X, Wang Y, Yuan K . TRIM59 as a novel molecular biomarker to predict the prognosis of patients with NSCLC. Oncol Lett. 2020; 19(2):1400-1408. PMC: 6956412. DOI: 10.3892/ol.2019.11199. View

20.

Han L, Lei G, Chen Z, Zhang Y, Huang C, Chen W . IGF2BP2 Regulates MALAT1 by Serving as an N6-Methyladenosine Reader to Promote NSCLC Proliferation. Front Mol Biosci. 2022; 8:780089. PMC: 8802805. DOI: 10.3389/fmolb.2021.780089. View